Table 1.

Examples of abstracts assessed

Abstract with no mention of funding source and CoI	Abstract reporting funding source only	Abstract reporting funding source and CoI
Efficacy and safety of experimental treatment A in combination with treatment B and treatment c in patients with mixed dyslipidemia.	Efficacy and safety of experimental treatment A in combination with treatment B and treatment c in patients with mixed dyslipidemia.	Efficacy and safety of experimental treatment A in combination with treatment B and treatment c in patients with mixed dyslipidemia.
AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G; Bishop D; Potter LM; Alyn JC	AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G; Bishop D; Potter LM; Alyn JC	AUTHORS: Thomson MR; Cook A; Pettigrew GE; Bower G; Bishop D; Potter LM; Alyn JC
BACKGROUND: Treatment B and treatment C combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia.	BACKGROUND: Treatment B and treatment C combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia.	BACKGROUND: Treatment B and treatment C combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia.
METHODS: In this phase 3, multicenter, double-blind study, a total of 543 patients with triglycerides >/=150 mg/dL and <400 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C >/=130 mg/dL were randomized to 12 weeks of treatment with experimental treatment A 135 mg or placebo, each coadministered with treatment B 40 mg + treatment C 10 mg (treatment BC).	METHODS: In this phase 3, multicenter, double-blind study, a total of 543 patients with triglycerides >/=150 mg/dL and <400 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C >/=130 mg/dL were randomized to 12 weeks of treatment with experimental treatment A 135 mg or placebo, each coadministered with treatment B 40 mg + treatment C 10 mg (treatment BC).	METHODS: In this phase 3, multicenter, double-blind study, a total of 543 patients with triglycerides >/=150 mg/dL and <400 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C >/=130 mg/dL were randomized to 12 weeks of treatment with experimental treatment A 135 mg or placebo, each coadministered with treatment B 40 mg + treatment C 10 mg (treatment BC).
RESULTS: Both treatment regimens lowered LDL-C by >50%; however, experimental treatment A and treatment BC resulted in significantly (P < .001) greater improvements in HDL-C (13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C (-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%) compared with treatment BC. Overall, adverse events were similar in the 2 treatment groups. No unexpected muscle, hepatic, or renal safety signals were identified with either treatment combination.	RESULTS: Both treatment regimens lowered LDL-C by >50%; however, experimental treatment A and treatment BC resulted in significantly (P < .001) greater improvements in HDL-C (13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C (-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%) compared with treatment BC. Overall, adverse events were similar in the 2 treatment groups. No unexpected muscle, hepatic, or renal safety signals were identified with either treatment combination.	RESULTS: Both treatment regimens lowered LDL-C by >50%; however, experimental treatment A and treatment BC resulted in significantly (P < .001) greater improvements in HDL-C (13.0% vs 4.2%), triglycerides (-57.3% vs -39.7%), non-HDL-C (-55.6% vs -51.0%), and apoprotein B (-49.1% vs -44.7%) compared with treatment BC. Overall, adverse events were similar in the 2 treatment groups. No unexpected muscle, hepatic, or renal safety signals were identified with either treatment combination.
CONCLUSIONS: In patients with mixed dyslipidemia, the combination of experimental treatment A + treatment BC significantly improved lipid and nonlipid parameters compared with treatment BC and was generally well tolerated.	CONCLUSIONS: In patients with mixed dyslipidemia, the combination of experimental treatment A + treatment BC significantly improved lipid and nonlipid parameters compared with treatment BC and was generally well tolerated.	CONCLUSIONS: In patients with mixed dyslipidemia, the combination of experimental treatment A + treatment BC significantly improved lipid and nonlipid parameters compared with treatment BC and was generally well tolerated.
	FUNDING: Abbott.	FUNDING: Abbott.
		CONFLICTS OF INTEREST: MRT, AC and GEP declared financial interest and/or other relationships with Abbott. GB, DB, LMP and JCA are employees of Abbott.

CoI, conflicts of interest.